Oruka Therapeutics (NASDAQ:ORKA) Sees Strong Trading Volume – Here’s Why

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares saw unusually-high trading volume on Wednesday . Approximately 1,455,683 shares were traded during trading, an increase of 79% from the previous session’s volume of 811,598 shares.The stock last traded at $70.72 and had previously closed at $73.99.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply raised multi-quarter and full‑year EPS forecasts, trimming losses across 2026–2027 and reiterating a “Buy” rating with a $120 price target — a clear analyst vote of confidence that supports upside and reduced downside risk from earlier expected losses. MarketBeat ORKA Analyst Note
• Positive Sentiment: Oruka reported positive Phase 2a results for ORKA‑001 in plaque psoriasis (efficacy/safety readouts), which materially de-risks the lead program and strengthens the company’s clinical narrative — a primary fundamental driver for biotech valuation. Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
• Neutral Sentiment: Stifel Nicolaus maintained its Buy rating on ORKA, adding further broker support but without a new price target — reinforces analyst backing but is not new catalyst. Stifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
• Neutral Sentiment: Oruka and its clinical data are getting wider market attention (features in listicles and a Seeking Alpha slide deck), which can boost retail/institutional interest and trading volume but doesn’t by itself change fundamentals. 5 Small-Cap Stocks That Are On Fire Right Now Seeking Alpha: Interim Results From EVERLAST‑A Study
• Negative Sentiment: Oruka priced an upsized $700M public offering at $72.50/share — proceeds can fund development but the deal represents potential near‑term dilution and selling pressure as shares are distributed, a common negative catalyst for existing holders. Oruka Therapeutics prices upsized $700M public offering at $72.50 per share

Analyst Ratings Changes

ORKA has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. UBS Group boosted their target price on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday. Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a report on Monday. Stifel Nicolaus boosted their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Finally, Wall Street Zen upgraded shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $120.80.

Oruka Therapeutics Stock Up 0.5%

The stock has a market capitalization of $3.43 billion, a price-to-earnings ratio of -36.78 and a beta of -0.54. The company’s fifty day simple moving average is $49.57 and its 200 day simple moving average is $36.87.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.16. As a group, analysts anticipate that Oruka Therapeutics, Inc. will post -2.25 earnings per share for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the transaction, the chief executive officer directly owned 927,309 shares in the company, valued at $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31. Following the completion of the transaction, the insider owned 33,377 shares in the company, valued at approximately $1,365,453.07. This represents a 18.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 23,765 shares of company stock worth $1,089,745. Corporate insiders own 24.69% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Y Intercept Hong Kong Ltd acquired a new position in shares of Oruka Therapeutics in the first quarter valued at about $1,811,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $67,000. Seven Fleet Capital Management LP acquired a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $159,000. Invesco Ltd. grew its stake in shares of Oruka Therapeutics by 777.1% in the fourth quarter. Invesco Ltd. now owns 143,121 shares of the company’s stock valued at $4,338,000 after acquiring an additional 126,803 shares in the last quarter. Finally, Virtus Investment Advisers LLC acquired a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $267,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.